Share chart Enanta Pharmaceuticals, Inc.
Extended chart
Simple chart
About Enanta Pharmaceuticals, Inc.
Enanta Pharmaceuticals, Inc., биотехнологическая компания, открывает и разрабатывает низкомолекулярные препараты для лечения вирусных инфекций и заболеваний печени. Его цели исследований и разработок включают респираторно-синцитиальный вирус, SARS-CoV-2, метапневмовирус человека и вирус гепатита B. Компания имеет совместную разработку и лицензионное соглашение с Abbott Laboratories для выявления, разработки и коммерциализации соединений ингибиторов протеазы NS3 и NS3/4A HCV, включая паритапревир и глекапревир для лечения хронического вируса гепатита С. Enanta Pharmaceuticals, Inc. more details| IPO date | 2013-03-21 |
|---|---|
| ISIN | US29251M1062 |
| Industry | Biotechnology |
| Sector | Health Care |
| Валюта | usd |
| Валюта отчета | usd |
| Див.доход ао | 0 |
| Сайт | https://www.enanta.com |
| Цена ао | 5.23 |
| Change price per day: | -0% (5.23) |
|---|---|
| Change price per week: | +3.36% (5.06) |
| Change price per month: | +6.09% (4.93) |
| Change price per 3 month: | -10.75% (5.86) |
| Change price per half year: | -48.37% (10.13) |
| Change price per year: | -60.79% (13.34) |
| Change price per 3 year: | -89.28% (48.77) |
| Change price per 5 year: | -88.98% (47.48) |
| Change price per year to date: | -9.04% (5.75) |
|
|
Underestimation
|
Efficiency
|
|||||||||||||||||||||||||||||||||||||
Dividends
|
Debt
|
Growth impulse
|
|||||||||||||||||||||||||||||||||||||
| Institutions | Volume | Share, % |
|---|---|---|
| Armistice Capital, LLC | 2064000 | 9.76 |
| Farallon Capital Management Llc | 2025000 | 9.57 |
| Blackrock Inc. | 1934711 | 9.14 |
| Vanguard Group Inc | 1793786 | 8.48 |
| Morgan Stanley | 1173058 | 5.54 |
| Northern Trust Corporation | 935493 | 4.42 |
| Acadian Asset Management. LLC | 842944 | 3.98 |
| Millennium Management LLC | 765141 | 3.62 |
| Krensavage Asset Management, LLC | 742824 | 3.51 |
| Shaw D.E. & Co., Inc. | 638168 | 3.02 |
| Head | Job title | Payment | Year of birth |
|---|---|---|---|
| Mr. Paul J. Mellett Jr. | Chief Financial & Administrative Officer | 666.84k | 1955 (70 years) |
| Dr. Yat Sun Or Ph.D. | Senior VP of Research & Development and Chief Scientific Officer | 729.31k | 1952 (73 years) |
| Ms. Tara Lynn Kieffer Ph.D. | Chief Product Strategy Officer | 496.85k | 1978 (47 years) |
| Mr. Brendan Luu | Chief Business Officer | 622.86k | 1975 (50 years) |
| Ms. Jennifer Viera | Senior Director of Investor Relations & Corporate Communications | N/A | |
| Mr. Nathaniel S. Gardiner J.D. | Consultant | 672.67k | 1954 (71 year) |
| Dr. Jay R. Luly Ph.D. | President, CEO & Director | 1.25M | 1956 (69 years) |
| Dr. Scott T. Rottinghaus M.D. | Senior VP & Chief Medical Officer | 616.73k | 1974 (51 year) |
| Mr. Matthew P. Kowalsky J.D. | Chief Legal Officer | 1973 (52 years) |
Address: United States, Watertown. MA, 500 Arsenal Street - open in Google maps, open in Yandex maps
Website: https://www.enanta.com
Website: https://www.enanta.com
